Venkatraman Radhakrishnan’s highlights from SIOP 2024 Day 2 and 3

The 56th Congress of the ‘Societe Internationale d’Oncologie Pediatrique’ (SIOP) is being held from October 17-20, 2024 in Honolulu, Hawaii, US.

The SIOP 2024 annual congress in Hawaii represents an exciting milestone for the organization. Hosting the event in the United States offers an excellent opportunity to receive valuable contributions from North American colleagues and institutions, including the Children’s Oncology Group. Additionally, the congress’s proximity to South-East Asia and Oceania is expected to enrich the event with the expertise and perspectives from these dynamic regions. Attendees will also have the chance to experience the unique charm of Hawaii as a host destination.

Participants are expecting a comprehensive program that is featuring keynote addresses, interactive workshops, and panel discussions focused on the latest advancements in pediatric oncology. The event is also providing ample networking opportunities, allowing attendees to connect with peers and share valuable insights that could influence the future of cancer care for children.

Venkatraman Radhakrishnan, Associate Professor of Medical and Pediatric Oncology at Chennai Cancer Institute, shared some highlights from SIOP 2024 Congress: 

“Linking free Cancer treatment with mandatory cancer registry information has improved registry data capture in Argentina.

Amazing work by Dr Florencia.”

“BENCHISTA project important for understanding variation in pediatric cancer survival across countries due to delay in diagnosis and advanced stage.”

“We need Momcology in India.

Patient engaged research.

Parent based registry.”

“GBD 2021 pediatric cancer burden.

Limited data from LMICs in Concord and international incidence of childhood cancer paper.

GBD and Globocan bridge the gap.”

“Rationale for Global Burden of Disease (GBD).

Different agency with different estimates.

GBD combines them.”

“Childhood cancer highest DALY among all cancer in low income countries.”

“GATA 2 mutation doesn’t influence outcome in MDS.“

“Therapeutic recommendation in JMML based on genetic alteration.“

“Vincristine neuropathy.

UKALL data.

VCR Dexa pulse randomization in maintenance.”

“Patients receiving VCR Dexa pulses in maintenance receive lesser 6PM and MTX.”

“On and off trial outcomes of ICICLE 14 ALL trial.

TMH data. Comparable demographics.

Not consenting for trial was adverse factor for EFS and OS.”

“Tata Bye Bye karyotyping, FISH, RT PCR, MLPA in pediatric ALL diagnosis using RNA seq and SNP.“

For more updates from SIOP 2024 Congress, follow OncoDaily.